Postmenopausal women are at a 35% increased risk of hip fractures if they regularly use proton pump inhibitors (PPIs), and that risk increases to more than 50% among women with a history of smoking.
For children with asthma without overt gastroesophageal reflux (GER), treatment with the proton pump inhibitor (PPI) lansoprazole is not associated with improved asthma control.
CutisPharma has launched the FIRST Omeprazole and FIRST Lansoprazole oral suspension compounding kits for pharmacists.
Novartis Consumer Health announced a voluntary recall of all lots of select bottle packaging configurations of the Excedrin product line and NoDoz (caffeine) products with expiry dates of December 20, 2014 or earlier, as well as all lots of Bufferin (aspirin) and Gas-X Prevention (simethicone) products with expiry dates of December 20, 2013 or earlier.
This patient information fact sheet provides information on the definition, causes, symptoms, risks, diagnostic tests and treatments for peptic ulcers.
Takeda announced that it has updated the product labeling for Dexilant (dexlansoprazole) to include information demonstrating that Dexilant had no clinically important effect on exposure to the active metabolite of clopidogrel (Plavix; Bristol-Myers Squibb and Sanofi) or clopidogrel-induced platelet inhibition.
AstraZeneca announced that the FDA has approved Nexium IV (esomeprazole sodium for injection) for use in children >1 month of age for the short-term treatment of gastroesophageal reflux disease (GERD) with erosive esophagitis when oral therapy is not possible or appropriate.
Teva Pharmaceuticals has voluntarily withdrawn its lansoprazole delayed-release orally disintegrating tablets (ODT) product from distribution after the FDA received reports of clogged and blocked oral syringes and feeding tubes when the drug is administered as a suspension through these devices.
XenoPort announced preliminary results from a Phase 2b clinical trial of arbaclofen placarbil (AP) as adjunctive therapy in patients with gastroesophageal reflux disease (GERD) who do not experience complete relief of GERD symptoms while being treated with a proton pump inhibitor (PPI).
The FDA has notified healthcare professionals and patients that prescription proton pump inhibitors may cause hypomagnesemia if taken for prolonged periods of time (in most cases, longer than one year).
